Nivolumab Outperforms Everolimus in Advanced RCC, Study Confirms
In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.
In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.
Bone metastases less predictive in the setting of cytoreductive nephrectomy.
In a study, metastasectomy was associated with significantly longer median progression-free and overall survival in some mRCC patients.
In a study, cytoreductive nephrectomy was not independently associated with improved survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitors.
Dual immunotherapy appears to have clinical efficacy beyond the first-line setting in patients with metastatic renal cell carcinoma with brain metastases.
In a small study, use of the potassium binder sodium zirconium cyclosilicate in transplant recipient did not appear to compromise immunosuppression with tacrolimus.
High CONUT scores were associated with adverse clinicopathological characteristics and worse survival in patients with localized upper tract urothelial carcinoma.
In a study of patients with upper tract urothelial carcinoma, variant vs conventional histology predicted worse survival.
Sterile pyuria may be a marker of inflammation, which is known to influence carcinogenesis.
Investigators found no meaningful survival difference between patients transitioning to home hemodialysis or peritoneal dialysis within 12 months of dialysis initiation.